Company research
BIOCRYST PHARMACEUTICALS INC
CIK 882796Updated Sep 27, 2026
SecurityBCRX · NASDAQ · equity
BCRX price & chart
Loading TradingView…
NASDAQ:BCRX on TradingView ↗About the company
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
In the news
BioCryst to Report Second Quarter 2026 Financial Results on August 5 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 514,158,000Source | 490,420,000Source | 516,960,000Source | 550,000,000Source |
| Property, Plant and Equipment, NetUSD | 8,783,000Source | 7,777,000Source | 7,910,000Source | 8,617,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 89,736,000Source | 104,713,000Source | 110,643,000Source | 304,767,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 106,818,000Source | 79,069,000Source | 56,950,000Source | 50,599,000Source |
| Inventory, NetUSD | 5,398,000Source | 31,274,000Source | 28,683,000Source | 27,533,000Source |
| Assets, CurrentUSD | 404,346,000Source | 421,968,000Source | 495,966,000Source | 516,500,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 17,182,000Source | 13,752,000Source | 19,542,000Source | 12,586,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,548,000Source | 8,061,000Source | 8,682,000Source | 6,806,000Source |
| Other Assets, NoncurrentUSD | 5,672,000Source | 5,157,000Source | 13,084,000Source | 6,806,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 633,311,000Source | 966,354,000Source | — | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,131,000Source | 2,085,000Source | 2,058,000Source | 1,879,000Source |
| Additional Paid in CapitalUSD | 1,384,857,000Source | 1,291,100,000Source | 1,222,236,000Source | 1,158,118,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,506,179,000Source | -1,770,040,000Source | -1,681,159,000Source | -1,454,620,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 38,000Source | 921,000Source | 1,337,000Source | 26,000Source |
| Stockholders' Equity Attributable to ParentUSD | -119,153,000Source | -475,934,000Source | -455,528,000Source | -294,597,000Source |
| Liabilities and EquityUSD | 514,158,000Source | 490,420,000Source | 516,960,000Source | 550,000,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 196,066,000Source | 160,384,000Source | 149,988,000Source | 105,514,000Source |
| Operating Lease, Liability, CurrentUSD | 317,000Source | 937,000Source | 1,058,000Source | 2,369,000Source |
| Accounts Payable, CurrentUSD | 15,826,000Source | 11,644,000Source | 20,893,000Source | 14,356,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,571,000Source | 7,924,000Source | 8,390,000Source | 5,804,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 126,413,000Source | 113,292,000Source | 102,882,000Source | 87,565,000Source |
| Deferred Revenue, CurrentUSD | — | — | 0Source | 1,224,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | 11,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 314,869,000Source | 303,231,000Source | 231,624,000Source |
| Short-term InvestmentsUSD | 185,011,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,389,000Source | 1,246,000Source | 1,655,000Source | 1,437,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 85,066,000Source | 65,413,000Source | 55,615,000Source | 44,701,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 1,639,000Source | 4,164,000Source | 1,450,000Source | 12,423,000Source |
| Increase (Decrease) in Accounts PayableUSD | 57,802,000Source | -62,379,000Source | -16,806,000Source | -22,360,000Source |
| Deferred Income Tax Expense (Benefit)USD | -1,212,000Source | -354,000Source | -682,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 347,369,000Source | -52,020,000Source | -95,141,000Source | -161,850,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -13,694,000Source | 52,593,000Source | -131,498,000Source | -128,238,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 8,847,000Source | 7,535,000Source | 2,172,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -349,931,000Source | -5,761,000Source | 32,485,000Source | 88,027,000Source |
| Repayments of Long-term DebtUSD | 300,000,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -14,986,000Source | -6,124,000Source | -193,792,000Source | -201,495,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 91,337,000Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 23,735,000Source | 30,383,000Source | 22,139,000Source | — |
| Income Taxes Paid, NetUSD | 2,803,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,270,000Source | -936,000Source | 362,000Source | 566,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 85,066,000Source | 65,413,000Source | 55,615,000Source | 44,701,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 3,566,000Source | — | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | 550,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -17,332,000Source | 0Source | -29,019,000Source | 0Source |
| Income Tax Expense (Benefit)USD | 3,530,000Source | 1,927,000Source | 310,000Source | 2,733,000Source |
| InterestExpenseNonoperatingUSD | 78,872,000Source | 98,516,000Source | — | — |
| Inventory Write-downUSD | 985,000Source | 1,350,000Source | 422,000Source | 932,000Source |
| Net Income (Loss) Attributable to ParentUSD | 263,861,000Source | -88,881,000Source | -226,539,000Source | -247,116,000Source |
| Nonoperating Income (Expense)USD | -73,598,000Source | -84,411,000Source | — | — |
| Operating Lease, ExpenseUSD | 2,007,000Source | 2,301,000Source | 2,018,000Source | 2,532,000Source |
| Payments of Financing CostsUSD | — | — | — | 34,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 0Source | 300,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 14,955,000Source |
| Restructuring CostsUSD | 6,314,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 874,837,000Source | 450,712,000Source | 331,412,000Source | 270,827,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 85,137,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 19,075,000Source | 12,269,000Source | 4,481,000Source | 6,408,000Source |
| Selling, General and Administrative ExpenseUSD | 348,647,000Source | 266,132,000Source | 213,894,000Source | 159,371,000Source |
| Operating Income (Loss)USD | 340,989,000Source | -2,543,000Source | -103,709,000Source | -148,435,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 267,391,000Source | -86,954,000Source | -226,229,000Source | -244,383,000Source |
| Income Tax Expense (Benefit)USD | 3,530,000Source | 1,927,000Source | 310,000Source | 2,733,000Source |
| Net Income (Loss) Attributable to ParentUSD | 263,861,000Source | -88,881,000Source | -226,539,000Source | -247,116,000Source |
| Earnings Per Share, BasicUSD per share | 1.26Source | -0.43Source | -1.18Source | -1.33Source |
| Earnings Per Share, DilutedUSD per share | 1.21Source | -0.43Source | -1.18Source | -1.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 209,893,000Source | 206,696,000Source | 192,198,000Source | 185,908,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 218,581,000Source | 206,696,000Source | 192,198,000Source | 185,908,000Source |
| Interest Expense (non-operating)USD | 78,872,000Source | 98,516,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 533,848,000Source | 453,255,000Source | 435,121,000Source | 419,262,000Source |
| Current Income Tax Expense (Benefit)USD | 4,742,000Source | 2,281,000Source | 992,000Source | 2,722,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 172,638,000Source | -62,515,000Source | -206,674,000Source | -225,127,000Source |
| Interest and Other IncomeUSD | 10,668,000Source | 14,746,000Source | — | — |
| Interest ExpenseUSD | — | — | 108,239,000Source | 99,092,000Source |
| Interest Expense, DebtUSD | — | — | — | 99,092,000Source |
| Nonoperating Income (Expense)USD | -73,598,000Source | -84,411,000Source | — | — |
| Operating Lease, ExpenseUSD | 2,007,000Source | 2,301,000Source | 2,018,000Source | 2,532,000Source |
| Other IncomeUSD | 12,090,000Source | — | — | — |
| Research and Development ExpenseUSD | 166,126,000Source | 174,638,000Source | 216,566,000Source | 253,297,000Source |
| Restructuring CostsUSD | 6,314,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 874,837,000Source | 450,712,000Source | 331,412,000Source | 270,827,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 85,137,000Source | — | — | — |
Offerings
Registration 333-291678
Filing attachments
ef20063492_ex99-1.htm · 8-K · 2026-01-23
EX-99.1 2 ef20063492_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema RESEARCH TRIANGLE PARK, N.C. - January 23, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s lon…
Read attachment ↗ef20063492_ex99-2.htm · 8-K · 2026-01-23
EX-99.2 3 ef20063492_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Astria Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) September 30, December 31, …
Read attachment ↗ny20057110x2_ex99-2.htm · S-4/A · 2025-12-15
EX-99.2 5 ny20057110x2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Consent of Evercore Group L.L.C. December 15, 2025 Astria Therapeutics, Inc. 22 Boston Wharf Road, 10th Floor Boston, MA 02210 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated October 13, 2025, to the Board of Directors of Astria Therapeutics, Inc. (“Astria”), as Annex C to, and reference thereto under the captions “Summary-Opinion of Astria’s Financial Advisor “, “The Merger-…
Read attachment ↗ef20060538_ex99-1.htm · 8-K · 2025-12-03
EX-99.1 2 ef20060538_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition RESEARCH TRIANGLE PARK, N.C. - December 3, 2025 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst’s proposed acquisition of Astria Therapeutics, Inc. (the “Merger”…
Read attachment ↗ny20057110x1_ex99-2.htm · S-4 · 2025-11-20
EX-99.2 5 ny20057110x1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Consent of Evercore Group L.L.C. November 20, 2025 Astria Therapeutics, Inc. 22 Boston Wharf Road, 10th Floor Boston, MA 02210 Members of the Board of Directors: We hereby consent to the inclusion of our opinion letter, dated October 13, 2025, to the Board of Directors of Astria Therapeutics, Inc. (“Astria”), as Annex C to, and reference thereto under the captions “Summary- Opinion of Astria’s Financial Advisor ”, “The Merger…
Read attachment ↗ef20057029_ex99-1.htm · 8-K · 2025-10-14
EX-99.1 3 ef20057029_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 VOTING AND SUPPORT AGREEMENT among BIOCRYST PHARMACEUTICALS, INC. and certain stockholders of ASTRIA THERAPEUTICS, INC. Dated as of October 14, 2025 VOTING AND SUPPORT AGREEMENT dated as of October 14, 2025 (this “Agreement”), among BioCryst Pharmaceuticals, Inc., a Delaware corporation (“Parent”) and each of the signatories named on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). Int…
Read attachment ↗